Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Jianwei Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8487-6728; OpenAlex author ID A5005868121. Sources: OpenAlex.

Their work

Papers
38 (first author 8, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2013: 1 paper · 2014: 5 papers · 2015: 3 papers · 2016: 5 papers · 2017: 3 papers · 2018: 2 papers · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: 3 papers · 2023: 4 papers · 2024: 2 papers · 2025: 4 papers

Papers 38

  1. Evaluation of Occult Liver Metastases in Pancreatic Adenocarcinoma by Diffusion-Weighted Related Magnetic Resonance Imaging. Co-author DOI 10.1002/jmri.29747↗
  2. Exploring the value of multiparametric quantitative MRI in the assessment of pancreatic ductal adenocarcinoma fibrosis grading. Co-author DOI 10.1007/s00330-024-11246-w↗
  3. Integrative analysis of pancreatic microbiota and metabolome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-27942-6↗
  4. CT-based radiomics models decode fibrosis content and molecular differences in pancreatic ductal adenocarcinoma: a multi-institutional study. Co-author DOI 10.1186/s13244-025-02036-z↗
  5. Corrigendum to "LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway" [Cancer Lett.374 (2016) 261-27… Co-author DOI 10.1016/j.canlet.2024.217239↗
  6. Editorial: Mechanism and treatment for pancreatic cancer metastases. Co-author DOI 10.3389/fonc.2024.1424817↗
  7. nc-RNA-mediated high expression of CDK6 correlates with poor prognosis and immune infiltration in pancreatic cancer. Co-author DOI 10.1002/cam4.5260↗
  8. The Role of Signaling Pathways in Pancreatic Cancer Targeted Therapy. Last author DOI 10.1097/coc.0000000000000979↗
  9. UCA1 executes an oncogenic role in pancreatic cancer by regulating miR-582-5p/BRCC3. Last author DOI 10.3389/fonc.2023.1133200↗
  10. Fibrinogen-to-prealbumin ratio: A new prognostic marker of resectable pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1149942↗
  11. Development and external validation of a radiomics combined with clinical nomogram for preoperative prediction prognosis of resectable pancreatic ductal adenoc… Co-author DOI 10.3389/fonc.2022.1037672↗
  12. LncRNA SNHG1 Promotes the Progression of Pancreatic Cancer by Regulating FGFR1 Expression via Competitively Binding to miR-497. Last author DOI 10.3389/fonc.2022.813850↗
  13. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Co-author DOI 10.3389/fonc.2022.965508↗
  14. Plasma-Derived Exosome MiR-19b Acts as a Diagnostic Marker for Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.739111↗
  15. Neoadjuvant therapy for pancreatic cancer: Limitations and advances of response assessment (Review). Co-author DOI 10.3892/or.2021.7977↗
  16. Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms. Co-author DOI 10.1016/j.pan.2019.08.008↗
  17. Synthesis of gold nanoparticles from leaf Panax notoginseng and its anticancer activity in pancreatic cancer PANC-1 cell lines. First author DOI 10.1080/21691401.2019.1593852↗
  18. Green synthesis of gold nanoparticles from Scutellaria barbata and its anticancer activity in pancreatic cancer cell (PANC-1). First author DOI 10.1080/21691401.2019.1594862↗
  19. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0777-7↗
  20. Immunotherapy for pancreatic cancer: A long and hopeful journey. Co-author DOI 10.1016/j.canlet.2018.03.040↗
  21. MicroRNA-221-3p is up-regulated and serves as a potential biomarker in pancreatic cancer. First author DOI 10.1080/21691401.2017.1315429↗
  22. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. First author DOI 10.1002/cam4.1071↗
  23. Early detection of pancreatic cancer: Where are we now and where are we going? First author DOI 10.1002/ijc.30670↗
  24. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Co-author DOI 10.1016/j.canlet.2017.01.041↗
  25. LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. Co-author DOI 10.1016/j.canlet.2016.02.018↗
  26. TUFT1 regulates metastasis of pancreatic cancer through HIF1-Snail pathway induced epithelial-mesenchymal transition. Co-author DOI 10.1016/j.canlet.2016.08.017↗
  27. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Co-author DOI 10.1097/sla.0000000000001345↗
  28. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. Co-author DOI 10.1186/s13046-016-0406-z↗
  29. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Co-author DOI 10.18632/oncotarget.9491↗
  30. Pancreatic cancer stem cells: new insight into a stubborn disease. First author DOI 10.1016/j.canlet.2014.12.004↗
  31. Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer. First author DOI 10.1186/s12957-015-0510-0↗
  32. MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP. First author DOI 10.1371/journal.pone.0116934↗
  33. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0092847↗
  34. CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Co-author DOI 10.18632/oncotarget.1890↗
  35. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Co-author DOI 10.18632/oncotarget.2184↗
  36. Stathmin, interacting with Nf-κB, promotes tumor growth and predicts poor prognosis of pancreatic cancer. Co-author DOI 10.2174/1566524014666140228120913↗
  37. PIM kinases: an overview in tumors and recent advances in pancreatic cancer. Co-author DOI 10.2217/fon.13.229↗
  38. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Co-author DOI 10.2174/1566524011313040001↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dexin Yu · 5 shared papers, 2022–2025 · strength 1.29
  2. Fangqing Wang · 4 shared papers, 2022–2025 · strength 1.07
  3. Sanyuan Hu · 10 shared papers, 2015–2021 · strength 0.87
  4. Lei Wang · 7 shared papers, 2017–2023 · strength 0.78
  5. Hanxiang Zhan · 8 shared papers, 2015–2024 · strength 0.74
  6. Yupei Zhao · 9 shared papers, 2014–2022 · strength 0.55
  7. Taiping Zhang · 10 shared papers, 2014–2019 · strength 0.54
  8. Wenyi Guo · 2 shared papers, 2023–2024 · strength 0.48
  9. Lei You · 9 shared papers, 2014–2019 · strength 0.48
  10. Feng Li · 3 shared papers, 2019–2025 · strength 0.48
  11. Hanxiang Zhan · 4 shared papers, 2016–2021 · strength 0.46
  12. Bin Zhou · 5 shared papers, 2016–2018 · strength 0.36
  13. Shihong Chen · 2 shared papers, 2021–2022 · strength 0.32
  14. Li Zhou · 6 shared papers, 2014–2019 · strength 0.32
  15. Lei Wang · 1 shared paper, 2024 · strength 0.31
  16. Guangyong Zhang · 4 shared papers, 2015–2018 · strength 0.31
  17. Xiaole Hu · 1 shared paper, 2023 · strength 0.31
  18. Hui Zhang · 1 shared paper, 2025 · strength 0.28
  19. Lei Wang · 1 shared paper, 2025 · strength 0.28
  20. Ce Li · 2 shared papers, 2016–2024 · strength 0.27
  21. Lei Wang · 2 shared papers, 2019 · strength 0.24
  22. Yiqing Zhu · 1 shared paper, 2025 · strength 0.24
  23. Xiao Liang · 1 shared paper, 2025 · strength 0.24
  24. Zhen Li · 1 shared paper, 2025 · strength 0.24
  25. Yifan Wang · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.